CN1403096A - 熊胆粉滴眼液及其制备方法 - Google Patents
熊胆粉滴眼液及其制备方法 Download PDFInfo
- Publication number
- CN1403096A CN1403096A CN02132983A CN02132983A CN1403096A CN 1403096 A CN1403096 A CN 1403096A CN 02132983 A CN02132983 A CN 02132983A CN 02132983 A CN02132983 A CN 02132983A CN 1403096 A CN1403096 A CN 1403096A
- Authority
- CN
- China
- Prior art keywords
- powder
- eye drop
- fel ursi
- bear
- bear bile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000843 powder Substances 0.000 title claims abstract description 53
- 239000003889 eye drop Substances 0.000 title claims abstract description 34
- 210000000941 bile Anatomy 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 7
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 7
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 235000019800 disodium phosphate Nutrition 0.000 claims description 6
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 5
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229940012356 eye drops Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000012958 reprocessing Methods 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 206010023332 keratitis Diseases 0.000 abstract description 11
- 230000001154 acute effect Effects 0.000 abstract description 9
- 201000007032 bacterial conjunctivitis Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 230000004438 eyesight Effects 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 201000010666 keratoconjunctivitis Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010001257 Adenoviral conjunctivitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000282443 Ursidae Species 0.000 description 1
- 241000282453 Ursus americanus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- UYTOIVSXYNMGQZ-UHFFFAOYSA-N [Na].[Na].[O].P(O)(O)(O)=O Chemical compound [Na].[Na].[O].P(O)(O)(O)=O UYTOIVSXYNMGQZ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000021373 epidemic keratoconjunctivitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 201000006476 shipyard eye Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
痊愈(例) | 显效(例) | 有效(例) | 无效(例) | 总有效率(%) | 总显效率(%) | |
治疗组 | 311 | 58 | 26 | 2 | 99 50 | 92.95 |
对照组 | 69 | 52 | 49 | 3 | 98.27 | 69.94 |
痊愈(只眼) | 显效(只眼) | 有效(只眼) | 无效(只眼) | 合计(只眼) | 总有效率(%) | 总显效率(%) | |
治疗组 | 346(81.41) | 54(12.71) | 25(5.88) | 0 | 425 | 100 | 94.12 |
对照组 | 66(43.42) | 44(28..95) | 42(27.63) | 0 | 152 | 100 | 72.37 |
痊愈(只眼) | 显效(只眼) | 有效(只眼) | 无效(只眼) | 合计(只眼) | 总有效率(%) | 总显效率(%) | |
治疗组 | 1955(70.91) | 51(18.55) | 26(9.45) | 3(1.09) | 275 | 98.91 | 89.46 |
对照组 | 52(35.62) | 42(28.77) | 46(31.51) | 6(4.10) | 146 | 95.89 | 64.38 |
实施例号 | 熊胆粉g | 磷酸二氢钠g | 磷酸氧二钠g | 氯化钠g | 对羟基苯甲酸乙酯g |
1 | 3.0 | 6.0 | 7.5 | 1.0 | 0.1 |
2 | 5.0 | 7.0 | 8.5 | 1.25 | 0.2 |
3 | 5.6 | 8.0 | 9.437 | 1.52 | 0.3 |
4 | 6.5 | 9.0 | 9.95 | 2.50 | 0.5 |
5 | 4.5 | 9.5 | 10.50 | 4.52 | 0.8 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021329834A CN1191074C (zh) | 2002-09-18 | 2002-09-18 | 熊胆粉滴眼液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021329834A CN1191074C (zh) | 2002-09-18 | 2002-09-18 | 熊胆粉滴眼液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1403096A true CN1403096A (zh) | 2003-03-19 |
CN1191074C CN1191074C (zh) | 2005-03-02 |
Family
ID=4747009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021329834A Expired - Lifetime CN1191074C (zh) | 2002-09-18 | 2002-09-18 | 熊胆粉滴眼液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1191074C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772420A (zh) * | 2012-08-08 | 2012-11-14 | 陕西省眼科研究所 | 一种猪胆汁酸盐滴眼液及其制备方法 |
CN103316085A (zh) * | 2013-07-08 | 2013-09-25 | 宋永心 | 一种治疗角结膜炎的藏药及其制备方法 |
CN108670979A (zh) * | 2018-06-21 | 2018-10-19 | 齐光伟 | 调血脂降胆固醇预防心脑血管病和动脉粥样硬化的熊胆粉 |
CN108743621A (zh) * | 2018-06-21 | 2018-11-06 | 齐光伟 | 冰晶态的熊胆粉和制备方法 |
CN110354143A (zh) * | 2018-03-26 | 2019-10-22 | 长春长庆药业集团有限公司 | 一种熊胆粉滴眼液原液的提取方法 |
CN114247208A (zh) * | 2021-12-15 | 2022-03-29 | 余盛武 | 基于胆红素用猪胆汁反向扭转式提取设备 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110392579B (zh) * | 2017-03-06 | 2022-11-08 | 坪田实验室股份有限公司 | 小鼠近视诱导模型及用于近视预防/抑制的内质网应激抑制剂 |
-
2002
- 2002-09-18 CN CNB021329834A patent/CN1191074C/zh not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102772420A (zh) * | 2012-08-08 | 2012-11-14 | 陕西省眼科研究所 | 一种猪胆汁酸盐滴眼液及其制备方法 |
CN102772420B (zh) * | 2012-08-08 | 2014-03-05 | 陕西省眼科研究所 | 一种猪胆汁酸盐滴眼液及其制备方法 |
CN103316085A (zh) * | 2013-07-08 | 2013-09-25 | 宋永心 | 一种治疗角结膜炎的藏药及其制备方法 |
CN103316085B (zh) * | 2013-07-08 | 2014-05-07 | 宋永心 | 一种治疗角结膜炎的藏药及其制备方法 |
CN110354143A (zh) * | 2018-03-26 | 2019-10-22 | 长春长庆药业集团有限公司 | 一种熊胆粉滴眼液原液的提取方法 |
CN108670979A (zh) * | 2018-06-21 | 2018-10-19 | 齐光伟 | 调血脂降胆固醇预防心脑血管病和动脉粥样硬化的熊胆粉 |
CN108743621A (zh) * | 2018-06-21 | 2018-11-06 | 齐光伟 | 冰晶态的熊胆粉和制备方法 |
CN114247208A (zh) * | 2021-12-15 | 2022-03-29 | 余盛武 | 基于胆红素用猪胆汁反向扭转式提取设备 |
Also Published As
Publication number | Publication date |
---|---|
CN1191074C (zh) | 2005-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2034956B2 (en) | Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis | |
WO2005009459A1 (en) | Ophthalmic compositions comprising trefoil factor family peptides | |
CN100525777C (zh) | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 | |
CN1191074C (zh) | 熊胆粉滴眼液及其制备方法 | |
CN113081956A (zh) | 一种氧化海藻酸钠改性的那他霉素滴眼液及其制备方法 | |
WO2022042541A1 (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
JPWO2008056786A1 (ja) | 皮膚又は粘膜適用組成物 | |
CN1895281A (zh) | 一种治疗急性角膜炎、缓解视疲劳的中药制剂及其制备工艺 | |
Logan et al. | Critical hypokalemic renal tubular acidosis due to Sjögren's syndrome: association with the purported immune stimulant echinacea. | |
CN110876715A (zh) | 一种鼻腔冲洗液 | |
CN112220740B (zh) | 一种鼻炎预防或治疗用抗菌消炎微凝胶及其制备方法和应用 | |
CN1132584C (zh) | 一种治疗近视的滴眼剂 | |
CN108403691A (zh) | 一种依达拉奉的新用途 | |
LU101523B1 (en) | Application of taraxasterone in a preparation of medicament for preventing and treating senile dementia | |
KR100963611B1 (ko) | 알긴산류 화합물을 포함하는 점안용 조성물 및 그의제조방법 | |
CN114796395A (zh) | 一种中药滴眼液及其应用 | |
LU101639B1 (en) | Application of Ilexgenin O in preparation of medicament for preventing and treating senile dementia | |
CN100563628C (zh) | 一种苄达赖氨酸眼用凝胶制剂及其制备方法 | |
WO2020147350A1 (zh) | 阿拉伯木聚糖磺酸盐在制备治疗骨关节炎的药物中的应用 | |
CN112546061A (zh) | 一种肝素类药物组合物、喷鼻剂及其制备方法及应用 | |
CN101342180A (zh) | 一种眼用药物组合物及其制备方法 | |
CN104622800A (zh) | 苄达赖氨酸滴眼液及制备方法 | |
KR20190004275A (ko) | 글리코겐 및 히알루론산 또는 이의 염의 상승 작용 조합을 포함하는 안과 조성물 | |
CN1198636C (zh) | 蒲公英制剂在制药中的应用 | |
CN112999340A (zh) | 一种鼻腔冲洗液及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WANG CHUNHONG Free format text: FORMER OWNER: WANG LI Effective date: 20090508 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090508 Address after: Jilin Province, Jilin City, Da Dong Jie Hu Tong Jianlin Chuanying District No. 8-1-1 Patentee after: Wang Chunhong Address before: Wang Pengzhuan, Jilin Hospital of traditional Chinese medicine, 45 North Avenue, camp, Jilin, Jilin Patentee before: Wang Li |
|
DD01 | Delivery of document by public notice |
Addressee: Wang Chunhong Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice |
Addressee: Wang Chunhong Document name: Notification of Termination of Patent Right |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050302 |